Aperio Group LLC increased its position in Pfizer, Inc. (NYSE:PFE) by 4.7% during the second quarter, Holdings Channel reports. The fund owned 3,200,175 shares of the biopharmaceutical company’s stock after buying an additional 143,322 shares during the period. Pfizer comprises approximately 0.7% of Aperio Group LLC’s investment portfolio, making the stock its 19th largest position. Aperio Group LLC’s holdings in Pfizer were worth $107,494,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in the company. Silvercrest Asset Management Group LLC boosted its stake in shares of Pfizer by 5.2% in the fourth quarter. Silvercrest Asset Management Group LLC now owns 2,791,070 shares of the biopharmaceutical company’s stock worth $90,654,000 after buying an additional 138,383 shares during the last quarter. Fiera Capital Corp boosted its stake in shares of Pfizer by 3.4% in the fourth quarter. Fiera Capital Corp now owns 104,800 shares of the biopharmaceutical company’s stock worth $3,404,000 after buying an additional 3,432 shares during the last quarter. Levin Capital Strategies L.P. boosted its stake in shares of Pfizer by 6.1% in the fourth quarter. Levin Capital Strategies L.P. now owns 8,312,581 shares of the biopharmaceutical company’s stock worth $269,993,000 after buying an additional 474,404 shares during the last quarter. Intellectus Partners LLC bought a new stake in shares of Pfizer during the fourth quarter worth $1,296,000. Finally, Moloney Securities Asset Management LLC bought a new stake in shares of Pfizer during the fourth quarter worth $809,000. Institutional investors and hedge funds own 70.10% of the company’s stock.

Shares of Pfizer, Inc. (PFE) traded up 0.21% during trading on Wednesday, reaching $33.35. 5,342,160 shares of the company were exchanged. The firm has a market cap of $199.03 billion, a price-to-earnings ratio of 24.40 and a beta of 1.00. Pfizer, Inc. has a 52-week low of $29.83 and a 52-week high of $35.38. The stock’s 50-day moving average is $33.43 and its 200-day moving average is $33.25.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.02. The business had revenue of $12.90 billion during the quarter, compared to analysts’ expectations of $13.08 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.11%. The business’s quarterly revenue was down 1.9% on a year-over-year basis. During the same period last year, the company posted $0.64 earnings per share. Equities research analysts predict that Pfizer, Inc. will post $2.56 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 1st. Shareholders of record on Friday, August 4th will be issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 3.85%. The ex-dividend date is Wednesday, August 2nd. Pfizer’s payout ratio is 94.12%.

COPYRIGHT VIOLATION WARNING: “Aperio Group LLC Boosts Stake in Pfizer, Inc. (NYSE:PFE)” was published by Daily Political and is owned by of Daily Political. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://www.dailypolitical.com/2017/08/09/aperio-group-llc-boosts-stake-in-pfizer-inc-nysepfe.html.

PFE has been the topic of a number of research reports. Jefferies Group LLC reiterated a “neutral” rating and set a $35.00 price target (up from $34.00) on shares of Pfizer in a research report on Thursday, April 13th. Sanford C. Bernstein reiterated a “buy” rating and set a $35.00 price target on shares of Pfizer in a research report on Monday, April 24th. BMO Capital Markets reiterated a “hold” rating and set a $33.00 price target on shares of Pfizer in a research report on Thursday, April 27th. Barclays PLC reissued a “buy” rating and issued a $38.00 price objective on shares of Pfizer in a report on Wednesday, May 3rd. Finally, Citigroup Inc. lowered Pfizer from a “neutral” rating to a “sell” rating and decreased their price objective for the stock from $38.00 to $31.00 in a report on Tuesday, May 16th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $37.77.

In other Pfizer news, CEO Ian C. Read sold 96,950 shares of the firm’s stock in a transaction on Friday, August 4th. The shares were sold at an average price of $34.00, for a total value of $3,296,300.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.06% of the company’s stock.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.